Skip to main content
SpringerLink
Log in

Tumor Stroma and the Antitumor Immune Response

  • Chapter
Tumor-Induced Immune Suppression

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Antonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J. H., et al. (2006). Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 12: 878–887.

    Article  PubMed  CAS  Google Scholar 

  • Antony, P. A., Piccirillo, C. A., Akpinarli, A., Finkelstein, S. E., Speiss, P. J., Surman, D. R., Palmer, D. C., Chan, C. C., Klebanoff, C. A., Overwijk, W. W., et al. (2005). CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174:2591–2601.

    PubMed  CAS  Google Scholar 

  • Arlen, P. M., Gulley, J. L., Parker, C., Skarupa, L., Pazdur, M., Panicali, D., Beetham, P., Tsang, K. Y., Grosenbach, D. W., Feldman, J., et al. (2006). A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12:1260–1269.

    Article  PubMed  CAS  Google Scholar 

  • Brent, L., and Medawar, P. (1966). Quantitative studies on tissue transplantation immunity. 8. The effects of irradiation. Proc Royal Soc Lond Ser B Biol Sci 165:413–423.

    Article  CAS  Google Scholar 

  • Bubenik, J. (2003). Tumour MHC class I downregulation and immunotherapy (review). Oncol Rep 10:2005–2008.

    PubMed  CAS  Google Scholar 

  • Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005). Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202:1691–1701.

    Article  PubMed  CAS  Google Scholar 

  • Ciernik, I. F., Romero, P., Berzofsky, J. A., and Carbone, D. P. (1999). Ionizing radiation enhances immunogenicity of cells expressing a tumor-specific T-cell epitope. Int J Radiat Oncol Biol Phys 45:735–741.

    Article  PubMed  CAS  Google Scholar 

  • Demaria, S., Bhardwaj, N., McBride, W. H., and Formenti, S. C. (2005). Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 63:655–666.

    Article  PubMed  Google Scholar 

  • Dudley, M. E., and Rosenberg, S. A. (2003). Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3:666–675.

    Article  PubMed  CAS  Google Scholar 

  • Dvorak, H. F. (1986). Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650–1659.

    Article  PubMed  CAS  Google Scholar 

  • Ferrara, N., Mass, R. D., Campa, C., and Kim, R. (2007). Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med 58:491–504.

    Article  PubMed  CAS  Google Scholar 

  • Gabrilovich, D. I. (2007). Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited. Lancet Oncol 8:2–3.

    Article  PubMed  Google Scholar 

  • Ganss, R., Ryschich, E., Klar, E., Arnold, B., and Hammerling, G. J. (2002). Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 62:1462–1770.

    PubMed  CAS  Google Scholar 

  • Garin-Chesa, P., Old, L. J., and Rettig, W. J. (1990). Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA 87:7235–7239.

    Article  PubMed  CAS  Google Scholar 

  • Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M., et al. (2005a). Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202:907–912.

    Article  CAS  Google Scholar 

  • Gattinoni, L., Klebanoff, C. A., Palmer, D. C., Wrzesinski, C., Kerstann, K., Yu, Z., Finkelstein, S. E., Theoret, M. R., Rosenberg, S. A., and Restifo, N. P. (2005b). Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115:1616–1626.

    Article  CAS  Google Scholar 

  • Gattinoni, L., Powell, D. J., Jr, Rosenberg, S. A., Restifo, N. P. (2006). Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6:383–393.

    Article  PubMed  CAS  Google Scholar 

  • Gribben, J. G., Ryan, D. P., Boyajian, R., Urban, R. G., Hedley, M. L., Beach, K., Nealon, P., Matulonis, U., Campos, S., Gilligan, T. D., et al. (2005). Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 11:4430–4436.

    Article  PubMed  CAS  Google Scholar 

  • Heath, W. R., and Carbone, F. R. (2005). Coupling and cross-presentation. Nature 434:27–28.

    Article  PubMed  CAS  Google Scholar 

  • Hicklin, D. J., Marincola, F. M., and Ferrone, S. (1999). HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 5:178–186.

    Article  PubMed  CAS  Google Scholar 

  • Ho, W. Y., Blattman, J. N., Dossett, M. L., Yee, C., and Greenberg, P. D. (2003). Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3:431–437.

    Article  PubMed  CAS  Google Scholar 

  • Holler, P. D., Chlewicki, L. K., and Kranz, D. M. (2003). TCRs with high affinity for foreign pMHC show self-reactivity. Nat Immunol 4:55–62.

    Article  PubMed  CAS  Google Scholar 

  • Holler, P. D., and Kranz, D. M. (2003). Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity 18:255–264.

    Article  PubMed  CAS  Google Scholar 

  • Ibe, S., Qin, Z., Schuler, T., Preiss, S., and Blankenstein, T. (2001). Tumor rejection by disturbing tumor stroma cell interactions. J Exp Med 194:1549–1559.

    Article  PubMed  CAS  Google Scholar 

  • Kaminski, M. S., Zasadny, K. R., Francis, I. R., Milik, A. W., Ross, C. W., Moon, S. D., Crawford, S. M., Burgess, J. M., Petry, N. A., Butchko, G. M., et al. (1993). Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 329:459–465.

    Article  PubMed  CAS  Google Scholar 

  • Kelly, T. (2005). Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist Updat 8:51–58.

    Article  PubMed  CAS  Google Scholar 

  • Khong, H. T., Wang, Q. J., and Rosenberg, S. A. (2004). Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother 27:184–190.

    Article  PubMed  Google Scholar 

  • Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841–844.

    Article  PubMed  CAS  Google Scholar 

  • Klebanoff, C. A., Gattinoni, L., Torabi-Parizi, P., Kerstann, K., Cardones, A. R., Finkelstein, S. E., Palmer, D. C., Antony, P. A., Hwang, S. T., Rosenberg, S. A., et al. (2005). Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 102:9571–9576.

    Article  PubMed  CAS  Google Scholar 

  • Klein, E., and Klein, G. (1972). Specificity of homograft rejection in vivo, assessed by inoculation of artificially mixed compatible and incompatible tumor cells. Cell Immunol 5:201–208.

    Article  Google Scholar 

  • Lake, R. A., and Robinson, B. W. (2005). Immunotherapy and chemotherapy—a practical partnership. Nat Rev Cancer 5:397–405.

    Article  PubMed  CAS  Google Scholar 

  • Liu, K., Caldwell, S. A., and Abrams, S. I. (2005). Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gamma-regulated gene expression. Cancer Res 65:4376–4388.

    Article  PubMed  CAS  Google Scholar 

  • Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., and Lord, E. M. (2005). Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 174:7516–7523.

    PubMed  CAS  Google Scholar 

  • Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139.

    Article  PubMed  CAS  Google Scholar 

  • Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126–129.

    Article  PubMed  CAS  Google Scholar 

  • Nair, S., Boczkowski, D., Moeller, B., Dewhirst, M., Vieweg, J., and Gilboa, E. (2003). Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102:964–971.

    Article  PubMed  CAS  Google Scholar 

  • Neijssen, J., Herberts, C., Drijfhout, J. W., Reits, E., Janssen, L., and Neefjes, J. (2005). Cross-presentation by intercellular peptide transfer through gap junctions. Nature 434:83–88.

    Article  PubMed  CAS  Google Scholar 

  • Niederman, T. M., Ghogawala, Z., Carter, B. S., Tompkins, H. S., Russell, M. M., and Mulligan, R. C. (2002). Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci USA 99:7009–7014.

    Article  PubMed  CAS  Google Scholar 

  • Nowak, A. K., Lake, R. A., Marzo, A. L., Scott, B., Heath, W. R., Collins, E. J., Frelinger, J. A., and Robinson, B. W. (2003). Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170:4905–4913.

    PubMed  CAS  Google Scholar 

  • Prehn, R. T. (1973). Destruction of tumor as an “innocent bystander” in an immune response specifically directed against nontumor antigens. Isr J Med Sci 9:375–379.

    PubMed  CAS  Google Scholar 

  • Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., Wansley, E. K., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006). Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203:1259–1271.

    Article  PubMed  CAS  Google Scholar 

  • Sanchez-Perez, L., Kottke, T., Diaz, R. M., Ahmed, A., Thompson, J., Chong, H., Melcher, A., Holmen, S., Daniels, G., and Vile, R. G. (2005). Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res 65:2009–2017.

    Article  PubMed  CAS  Google Scholar 

  • Schreiber, H. (ed.) (2003). Tumor Immunology, 5th edn. Philadelphia, PA: Lippincott-Williams & Wilkins, pp. 1557–1592.

    Google Scholar 

  • Scott, A. M., Wiseman, G., Welt, S., Adjei, A., Lee, F. T., Hopkins, W., Divgi, C. R., Hanson, L. H., Mitchell, P., Gansen, D. N., et al. (2003). A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 9:1639–1647.

    PubMed  CAS  Google Scholar 

  • Seemayer, T. A., Lagace, R., Schurch, W., and Tremblay, G. (1979). Myofibroblasts in the stroma of invasive and metastatic carcinoma: a possible host response to neoplasia. Am J Surg Pathol 3:525–533.

    Article  PubMed  CAS  Google Scholar 

  • Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792.

    Article  PubMed  CAS  Google Scholar 

  • Spiotto, M. T., Rowley, D. A., and Schreiber, H. (2004). Bystander elimination of antigen loss variants in established tumors. Nat Med 10:294–298.

    Article  PubMed  CAS  Google Scholar 

  • Spiotto, M. T., and Schreiber, H. (2005). Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells. Cancer Immun 5:8.

    PubMed  Google Scholar 

  • Sweeney, C. J., Miller, K. D., and Sledge, G. W., Jr (2003). Resistance in the anti-angiogenic era: nay-saying or a word of caution? Trends Mol Med 9:24–29.

    Article  PubMed  CAS  Google Scholar 

  • Weissman, I. L. (1973). Tumor immunity in vivo: evidence that immune destruction of tumor leaves “bystander” cells intact. J Natl Cancer Inst 51:443–448.

    PubMed  CAS  Google Scholar 

  • Wesley, U. V., Albino, A. P., Tiwari, S., and Houghton, A. N. (1999). A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med 190:311–322.

    Article  PubMed  CAS  Google Scholar 

  • Wheeler, C. J., Das, A., Liu, G., Yu, J. S., and Black, K. L. (2004). Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 10:5316–5326.

    Article  PubMed  CAS  Google Scholar 

  • Yamshchikov, G. V., Mullins, D. W., Chang, C. C., Ogino, T., Thompson, L., Presley, J., Galavotti, H., Aquila, W., Deacon, D., Ross, W., et al. (2005). Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J Immunol 174:6863–6871.

    PubMed  CAS  Google Scholar 

  • Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., and Rosenberg, S. A. (2003). A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434.

    Article  PubMed  CAS  Google Scholar 

  • Yu, Z., Theoret, M. R., Touloukian, C. E., Surman, D. R., Garman, S. C., Feigenbaum, L., Baxter, T. K., Baker, B. M., and Restifo, N. P. (2004). Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J Clin Invest 114:551–559.

    Article  PubMed  CAS  Google Scholar 

  • Zhang, B., Bowerman, N. A., Salama, J. K., Schmidt, H., Spiotto, M. T., Schietinger, A., Yu, P., Fu, Y. X., Weichselbaum, R. R., Rowley, D. A., et al. (2007). Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 204:49–55.

    Article  PubMed  CAS  Google Scholar 

  • Zhou, G., Lu, Z., McCadden, J. D., Levitsky, H. I., and Marson, A. L. (2004). Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med 200:1581–1592.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Department of Pathology and the Committee on Immunology, University of Chicago, 5841 S. Maryland, MC3083, Chicago, IL 60637, USA

    Hans Schreiber

Authors
  1. Bin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donald A. Rowley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hans Schreiber
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL 33612, USA

    Dmitry I. Gabrilovich

  2. Laboratory of Molecular Immunoregulation, National Cancer Institute, Frederick, MD 21071, USA

    Arthur A. Hurwitz

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Zhang, B., Rowley, D.A., Schreiber, H. (2008). Tumor Stroma and the Antitumor Immune Response. In: Gabrilovich, D.I., Hurwitz, A.A. (eds) Tumor-Induced Immune Suppression. Springer, New York, NY. https://doi.org/10.1007/978-0-387-69118-3_13

Download citation

Publish with us

Policies and ethics

Search

Navigation